Pre-commercial pharma companies face a common choice: commercialize products independently or collaborate with another pharmaceutical company as a commercialization partner. As the C-suite leaders in these organizations wrestle with the pros and cons of this choice, one factor they must consider is the impact their decision will have on their current and future market valuation.
The question is this: How much of a premium does the market put on a company that chooses to launch and commercialize its product independently?
This white paper dives deep into the data and discusses how the average market capitalization of a cohort of public companies that developed paths to launch their own products (including successful and sub-optimal launches) can be over six times greater than a cohort of public companies who consistently license with other pharma companies to launch their products.
Download the white paper to learn more about the following topics:
- Launch Can Be Too Expensive and Complex to Execute Independently
- Realizing Sub-optimal Value Creates a Microcap Trap
- Launch Is the Way Out of the Trap, But It’s Not So Easy
Author
Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence.
In more than 20 years of consulting and leadership in APAC, Ravi’s expertise has focused on helping clients take big-bet investments in complex and uncertain environments at an asset and portfolio levels. Ravi regularly…
Sowbhagya is an Associate Consultant at EVERSANA APAC. She has more than 2 years of experience in healthcare. She has worked with several MNC clients on market entry assessments, valuation of assets in rare…